Cargando…

Venetoclax, a BCL-2 Inhibitor, Enhances the Efficacy of Chemotherapeutic Agents in Wild-Type ABCG2-Overexpression-Mediated MDR Cancer Cells

Previous studies have shown that small-molecule BCL-2 inhibitors can have a synergistic interaction with ABCG2 substrates in chemotherapy. Venetoclax is a potent and selective BCL-2 inhibitor, approved by the FDA in 2016 for the treatment of patients with chronic lymphocytic leukemia (CLL). This stu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Jing-Quan, Li, Jonathan Y., Teng, Qiu-Xu, Lei, Zi-Ning, Ji, Ning, Cui, Qingbin, Zeng, Leli, Pan, Yihang, Yang, Dong-Hua, Chen, Zhe-Sheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072352/ https://www.ncbi.nlm.nih.gov/pubmed/32085398 http://dx.doi.org/10.3390/cancers12020466

Ejemplares similares

Overexpression of ABCG2 Confers Resistance to MLN7243, a Ubiquitin-Activating Enzyme (UAE) Inhibitor
por: Wu, Zhuo-Xun, et al.
Publicado: (2021)

Reversal of Cancer Multidrug Resistance (MDR) Mediated by ATP-Binding Cassette Transporter G2 (ABCG2) by AZ-628, a RAF Kinase Inhibitor
por: Wang, Jing-Quan, et al.
Publicado: (2020)

Reversal Effect of ALK Inhibitor NVP-TAE684 on ABCG2-Overexpressing Cancer Cells
por: Wang, Jingqiu, et al.
Publicado: (2020)

WHI-P154 enhances the chemotherapeutic effect of anticancer agents in ABCG2-overexpressing cells
por: Zhang, Hui, et al.
Publicado: (2014)

Rociletinib (CO-1686) enhanced the efficacy of chemotherapeutic agents in ABCG2-overexpressing cancer cells in vitro and in vivo
por: Zeng, Fanpu, et al.
Publicado: (2020)

The Novel benzamide Derivative, VKNG-2, Restores the Efficacy of Chemotherapeutic Drugs in Colon Cancer Cell Lines by Inhibiting the ABCG2 Transporter
por: Narayanan, Silpa, et al.
Publicado: (2021)

VS-4718 Antagonizes Multidrug Resistance in ABCB1- and ABCG2-Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC Transporters
por: Ji, Ning, et al.
Publicado: (2018)

Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo
por: Hu, Jing, et al.
Publicado: (2015)

Sitravatinib Sensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs
por: Wu, Chung-Pu, et al.
Publicado: (2020)

GSK2606414 Sensitizes ABCG2-Overexpressing Multidrug-Resistant Colorectal Cancer Cells to Chemotherapeutic Drugs
por: Yu, Ze-Zhong, et al.
Publicado: (2023)

Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells
por: Zhang, Wei, et al.
Publicado: (2018)

ABCG2 Overexpression Contributes to Pevonedistat Resistance
por: Kathawala, Rishil J., et al.
Publicado: (2020)

Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells
por: Cui, Qingbin, et al.
Publicado: (2019)

KD025, an anti-adipocyte differentiation drug, enhances the efficacy of conventional chemotherapeutic drugs in ABCG2-overexpressing leukemia cells
por: Jing, Wen, et al.
Publicado: (2020)

Lazertinib improves the efficacy of chemotherapeutic drugs in ABCB1 or ABCG2 overexpression cancer cells in vitro, in vivo, and ex vivo
por: Fan, Yingfang, et al.
Publicado: (2022)

OTS964, a TOPK Inhibitor, Is Susceptible to ABCG2-Mediated Drug Resistance
por: Yang, Yuqi, et al.
Publicado: (2021)

ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
por: Cang, Shundong, et al.
Publicado: (2015)

Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition
por: Roca-Portoles, Alba, et al.
Publicado: (2020)

Methyl-Cantharidimide (MCA) Has Anticancer Efficacy in ABCB1- and ABCG2-Overexpressing and Cisplatin Resistant Cancer Cells
por: Li, Yi-Dong, et al.
Publicado: (2020)

The BCL2 Inhibitor Venetoclax Plus Rituximab Is Active in MYD88 Wild-Type Polyneuropathy With Anti-MAG Antibodies
por: Briani, Chiara, et al.
Publicado: (2022)

Sapitinib Reverses Anticancer Drug Resistance in Colon Cancer Cells Overexpressing the ABCB1 Transporter
por: Gao, Hai-Ling, et al.
Publicado: (2020)

Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance
por: Wu, Zhuo-Xun, et al.
Publicado: (2020)

Dual TTK/CLK2 inhibitor, CC‐671, selectively antagonizes ABCG2‐mediated multidrug resistance in lung cancer cells
por: Wu, Zhuo‐Xun, et al.
Publicado: (2020)

DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition
por: Kerkhofs, Martijn, et al.
Publicado: (2020)

Sitravatinib, a Tyrosine Kinase Inhibitor, Inhibits the Transport Function of ABCG2 and Restores Sensitivity to Chemotherapy-Resistant Cancer Cells in vitro
por: Yang, Yuqi, et al.
Publicado: (2020)

VKNG-1 Antagonizes ABCG2-Mediated Multidrug Resistance via p-AKT and Bcl-2 Pathway in Colon Cancer: In Vitro and In Vivo Study
por: Narayanan, Silpa, et al.
Publicado: (2021)

A-803467, a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2-mediated MDR in vitro and in vivo
por: Anreddy, Nagaraju, et al.
Publicado: (2015)

Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo
por: Guo, Xiaoran, et al.
Publicado: (2018)

SOX4 contributes to the progression of cervical cancer and the resistance to the chemotherapeutic drug through ABCG2
por: Sun, R, et al.
Publicado: (2015)

CM082 Enhances the Efficacy of Chemotherapeutic Drugs by Inhibiting the Drug Efflux Function of ABCG2
por: Xu, Lejia, et al.
Publicado: (2019)

CM082 Enhances the Efficacy of Chemotherapeutic Drugs by Inhibiting the Drug Efflux Function of ABCG2
por: Xu, Lejia, et al.
Publicado: (2023)

Targeting BCL2 with venetoclax is a promising therapeutic strategy for “double-proteinexpression” lymphoma with MYC and BCL2 rearrangements
por: Uchida, Akiko, et al.
Publicado: (2019)

Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations
por: Birkinshaw, Richard W., et al.
Publicado: (2019)

Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies
por: Yue, XiaoYan, et al.
Publicado: (2020)

Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2
por: Xu, Xi, et al.
Publicado: (2023)

PB1893: CLONAL EVOLUTION WITH BCL-2 AMPLIFICATION DURING VENETOCLAX TREATMENT
por: Rodríguez-Afonso, Jorge, et al.
Publicado: (2023)

The AKT inhibitor, MK-2206, attenuates ABCG2-mediated drug resistance in lung and colon cancer cells
por: Gao, Hai-Ling, et al.
Publicado: (2023)

Overcoming Multidrug Resistance via Photodestruction of ABCG2-Rich Extracellular Vesicles Sequestering Photosensitive Chemotherapeutics
por: Goler-Baron, Vicky, et al.
Publicado: (2012)

M3814, a DNA-PK Inhibitor, Modulates ABCG2-Mediated Multidrug Resistance in Lung Cancer Cells
por: Wu, Zhuo-Xun, et al.
Publicado: (2020)

MiR‐548 K regulatory effect on the ABCG2 gene expression in MDR breast cancer cells
por: Saberiyan, Mohammadreza, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3dk5i6e96tjsi4utbnjmg7028b